VPC
ANRO icon

Vestal Point Capital’s Alto Neuroscience ANRO Stock Holding History

Vestal Point Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.4M Sell
2,064,075
-420,925
-17% -$7.8M 1.3% 28
2025
Q4 		$44.2M Buy
2,485,000
+1,535,000
+162% +$19.3M 1.5% 22
2025
Q3 		$3.82M Hold
950,000
– – 0.17% 69
2025
Q2 		$2.09M Buy
950,000
+35,000
+4% +$83.3K 0.11% 62
2025
Q1 		$1.98M Hold
915,000
– – 0.14% 55
2024
Q4 		$3.87M Buy
915,000
+265,000
+41% +$1.65M 0.23% 58
2024
Q3 		$7.44M Buy
650,000
+30,000
+5% +$367K 0.56% 42
2024
Q2 		$6.63M Buy
620,000
+370,000
+148% +$4.82M 0.49% 41
2024
Q1 		$3.84M Buy
+250,000
New +$3.91M 0.32% 48

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Vestal Point Capital's ANRO Position: Q1 2026 in Review

Vestal Point Capital reduced its Alto Neuroscience (ANRO) stake by 17% in Q1 2026, selling an estimated $7.8M and leaving 2,064,075 shares worth $46.4M. The position accounts for 1.3% of the portfolio, ranked #28.

Vestal Point Capital first reported a position in ANRO in Q1 2024 and has held it in 9 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Vestal Point Capital held 2,064,075 shares of Alto Neuroscience worth $46.4M as of Q1 2026.
  • Vestal Point Capital sold 420,925 Alto Neuroscience shares in Q1 2026, an estimated $7.8M.
  • Alto Neuroscience made up 1.3% of Vestal Point Capital's portfolio in Q1 2026, its #28 holding.
  • Vestal Point Capital first reported a position in Alto Neuroscience in Q1 2024 and has held it in 9 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.